Daihan Pharmaceutical Co.Ltd Capital Reinvestment Ratio
Daihan Pharmaceutical Co.Ltd capital reinvestment ratio. Daihan Pharmaceutical Co.Ltd (023910) has a Capital Reinvestment Ratio of 1.14x as of September 2025, meaning it reinvests 1% of its operating cash flow (₩9.47 Billion) in capital expenditures (₩10.79 Billion). See Daihan Pharmaceutical Co.Ltd free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Daihan Pharmaceutical Co.Ltd (2014–2024)
Capital reinvestment ratio of Daihan Pharmaceutical Co.Ltd from 2014 to 2024. This chart tracks Daihan Pharmaceutical Co.Ltd's Capital Reinvestment Ratio across 11 annual periods. See financial agility of Daihan Pharmaceutical Co.Ltd to measure the company's free cash flow as a share of total liabilities.
Daihan Pharmaceutical Co.Ltd Capital Reinvestment Ratio by Year (2014–2024)
Daihan Pharmaceutical Co.Ltd capital reinvestment ratio by year from 2014 to 2024. For the full cash flow conversion analysis, see Daihan Pharmaceutical Co.Ltd (023910) cash conversion ratio.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.44x | ₩35.64 Billion | ₩15.80 Billion | ▼ -19.0% |
| 2023 | 0.55x | ₩38.86 Billion | ₩21.28 Billion | ▲ +84.2% |
| 2022 | 0.30x | ₩29.00 Billion | ₩8.62 Billion | ▲ +1.9% |
| 2021 | 0.29x | ₩40.62 Billion | ₩11.85 Billion | ▲ +83.0% |
| 2020 | 0.16x | ₩33.63 Billion | ₩5.36 Billion | ▼ -67.5% |
| 2019 | 0.49x | ₩35.26 Billion | ₩17.30 Billion | ▼ -52.8% |
| 2018 | 1.04x | ₩44.94 Billion | ₩46.69 Billion | ▲ +1.0% |
| 2017 | 1.03x | ₩20.45 Billion | ₩21.05 Billion | ▲ +31.2% |
| 2016 | 0.78x | ₩27.92 Billion | ₩21.90 Billion | ▲ +255.8% |
| 2015 | 0.22x | ₩17.98 Billion | ₩3.96 Billion | ▼ -80.0% |
| 2014 | 1.10x | ₩9.48 Billion | ₩10.47 Billion | — |